Until now, Cytokinetics, Inc. has had a pretty rotten year, with failures both regulatory and clinical seeing off two of its major pipeline hopes. But 2023 has ended in a blaze of glory thanks to aficamten, the cardiac myosin inhibitor that was its last remaining late-stage asset.
Cytokinetics Gets A Belated Christmas Present
Aficamten hits nicely in its pivotal hypertrophic cardiomyopathy trial, and a deal will surely follow.
